|
Name |
(S)-beta-hydroxypalmitic acid
|
| Molecular Formula | C16H32O3 | |
| IUPAC Name* |
(3S)-3-hydroxyhexadecanoic acid
|
|
| SMILES |
CCCCCCCCCCCCC[C@@H](CC(=O)O)O
|
|
| InChI |
InChI=1S/C16H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15(17)14-16(18)19/h15,17H,2-14H2,1H3,(H,18,19)/t15-/m0/s1
|
|
| InChIKey |
CBWALJHXHCJYTE-HNNXBMFYSA-N
|
|
| Synonyms |
(S)-beta-hydroxypalmitic acid; 3S-hydroxypalmitic acid; 3S-hydroxyhexadecanoic acid; (S)-3-hydroxypalmitic acid; (3S)-3-hydroxyhexadecanoic acid; (s)-3-hydroxyhexadecanoic acid; SCHEMBL6232663; CHEBI:37250; LMFA01050365; ZINC32838986; 16:0(3-OH); Q27117079
|
|
| CAS | 83780-74-9 | |
| PubChem CID | 10989404 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 272.42 | ALogp: | 5.8 |
| HBD: | 2 | HBA: | 3 |
| Rotatable Bonds: | 14 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 57.5 | Aromatic Rings: | 0 |
| Heavy Atoms: | 19 | QED Weighted: | 0.437 |
| Caco-2 Permeability: | -5.029 | MDCK Permeability: | 0.00003840 |
| Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.173 |
| Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.996 |
| 30% Bioavailability (F30%): | 0.983 |
| Blood-Brain-Barrier Penetration (BBB): | 0.273 | Plasma Protein Binding (PPB): | 97.15% |
| Volume Distribution (VD): | 0.364 | Fu: | 1.65% |
| CYP1A2-inhibitor: | 0.082 | CYP1A2-substrate: | 0.185 |
| CYP2C19-inhibitor: | 0.079 | CYP2C19-substrate: | 0.273 |
| CYP2C9-inhibitor: | 0.252 | CYP2C9-substrate: | 0.984 |
| CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.048 |
| CYP3A4-inhibitor: | 0.015 | CYP3A4-substrate: | 0.026 |
| Clearance (CL): | 5.926 | Half-life (T1/2): | 0.741 |
| hERG Blockers: | 0.047 | Human Hepatotoxicity (H-HT): | 0.041 |
| Drug-inuced Liver Injury (DILI): | 0.019 | AMES Toxicity: | 0.006 |
| Rat Oral Acute Toxicity: | 0.011 | Maximum Recommended Daily Dose: | 0.451 |
| Skin Sensitization: | 0.856 | Carcinogencity: | 0.127 |
| Eye Corrosion: | 0.984 | Eye Irritation: | 0.987 |
| Respiratory Toxicity: | 0.763 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001612 | ![]() |
0.830 | D07ILQ | ![]() |
0.548 | ||
| ENC002101 | ![]() |
0.742 | D0P1RL | ![]() |
0.531 | ||
| ENC000378 | ![]() |
0.719 | D0Z5SM | ![]() |
0.529 | ||
| ENC001217 | ![]() |
0.716 | D0O1PH | ![]() |
0.526 | ||
| ENC000466 | ![]() |
0.712 | D05ATI | ![]() |
0.493 | ||
| ENC003362 | ![]() |
0.694 | D00AOJ | ![]() |
0.446 | ||
| ENC000972 | ![]() |
0.689 | D0XN8C | ![]() |
0.418 | ||
| ENC000050 | ![]() |
0.677 | D00FGR | ![]() |
0.407 | ||
| ENC001159 | ![]() |
0.676 | D0I4DQ | ![]() |
0.386 | ||
| ENC000781 | ![]() |
0.667 | D0T9TJ | ![]() |
0.373 | ||